Antibiotic resistance: Prospects for the new millennium

Journal of Chemotherapy

Volumn 13, Issue 6, 2001, Pages 587-594

  Daw, M A ^a   Drah, Mohamed A ^a  

^a UNIVERSITY OF TRIPOLI   (Libyan Arab Jamahiriya)

Author keywords

Antibiotic resistance; Cycling antibiotics; Epidemiology; Infection control; Multi drug resistance; Peptides; Prebiotics; Probiotics

Indexed keywords

ANTIBIOTIC AGENT; CATION; CLOSTRIDIUM DIFFICILE TOXIN B; PEPTIDE; PREBIOTIC AGENT; PROBIOTIC AGENT; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; BIFIDOBACTERIUM; DRUG INDUSTRY; DRUG LEGISLATION; ECONOMIC ASPECT; EDUCATION; ENTEROCOCCUS; ENVIRONMENTAL FACTOR; GOVERNMENT; HEALTH CARE PERSONNEL; HEALTH CARE POLICY; HUMAN; INFECTION CONTROL; LACTOBACILLUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MULTIDRUG RESISTANCE; POLITICS; REVIEW; SACCHAROMYCES BOULARDII; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES; TREATMENT OUTCOME;

EID: 0035691095     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2001.13.6.587     Document Type: Review

References (63)

1. Leading article. Antibiotic policies, practices and pressures
2. Microbes, chemotherapy, evolution, and folly
3. Emergence of vancomycin resistance in Staphylococcus aureus
4. Antimicrobial resistance in developing countries
5. Value of surveillance cultures in the management of neutropenic patients
6. The crisis in antibiotic resistance
7. Beta-lactamases: Quality and resistance
8. Surveillance cultures in neutropenic patients
9. Prevention of Gram-negative infection in neutropenic cancer patients
10. A preventive strategies of MRSA among Libyan hospitals
11. Occurrence of high-level aminoglycoside resistance in environmental isolates of enterococci
12. Characterization of glycopeptide resistance in enterococci from USA hospitals
13. Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus
14. Treatment options for resistant pneumococcal infections
15. Antibiotic resistance; an impending crisis
16. The contribution of antibiotic use on the frequency of antibiotic resistance in hospital
17. Antimicrobial resistance in hospital organisms and its relation to antibiotic use
18. Outbreak of vancomycin-ampicillin and aminoglycoside-resistant Enterococcus faecium bacteremia in an adult oncology unit
19. Enterococcus faecium in hospitals
20. Empirical antibacterial treatment for sepsis and the role of glycopeptides: Recommendations from a European panel
21. Nosocomial outbreak due to Enterococcus faecium highly resistant to vancomycin, penicillin and gentamicin
22. Do antimicrobials increase the carriage rate of penicillin resistant pneumococci in children? Cross sectional prevalence study
23. Genetic analysis of a plasmid-encoded host genotype-specific enhancement of bacterial fitness
24. Multi-drug resistance - A sign of the times
25. Antimicrobial use in animals and its consequences for human health
26. Development of antibiotic resistance: A vet's tale
27. Environmental factors contributing to antibiotic resistance
28. Antibiotic usage and the incidence of resistance
29. Growth in the use of antibiotics in the community in England and Scotland in 1980-93
30. In appropriateness and variability of antibiotic prescription among French office-based physicians
31. Low dosage and long treatment duration of beta-lactam: Risk-factors for carriage of penicillin-resistant Streptococcus pneumoniae
32. Antibiotic resistant bacteria may outweigh their susceptible homologues
33. Is antimicrobial resistance in hospital microorganism related to antibiotic use?
34. Controlling glycopeptide-resistant enterococci
35. Control of prolonged outbreak of extended spectrum beta-lactamase-producing enterobacteriaceae in a university hospital
36. Revised guide lines for the control of methicillin-resistant Staphylococcus aureus infection in hospitals. Combined working party group of the BSAC, HIS, & ICNA
37. Report of a combined Working Party of the British Society for Antimicrobial Chemotherapy and the Hospital Infection Society. Guidelines on the control of methicillin resistant Staphylococcus aureus in the community
38. Preventing the emergence of multi-drug-resistant microorganisms through antimicrobial use controls: The complexity of the problem
39. Strategies to prevent and control the emergence and spread of antimicrobial resistant organisms in hospitals. A challenge to hospital leadership
40. New approaches to control of infections caused by antibiotic-resistant bacteria; an industry perspective
41. Antibiotic resistance: A view from the pharmaceutical industry
42. Cycling of antibiotics: An approach to circumvent resistance in specialized units of the hospital
43. Circumventing antibiotic resistance in specialized hospital units
44. Circumventing antibiotic resistance in specialized hospital units
45. Clinical and epidemiological features of Pseudomonas aeruginosa at the Libyan hospitals
46. Population biology, evolution and infectious disease: Convergence and synthesis
47. Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for potential treatment of multi-drug resistant gram negative bacterial infections
48. Everninomicin, an oligosaccharides antibiotic; its antimicrobial activity, post-antibiotic effect and synergistic bactericidal activity
49. Cationic antibacterial peptides
50. Antimicrobial peptides: Broad spectrum antibiotics from nature
51. Improvement of outer membrane-permeabilization and lipopolysaccharide-binding activities of an antimicrobial cationic peptide by C-terminal modification
52. Peptides and protein antimicrobial agents
53. Beta-lactm antibiotic potentiate magainin 2 antimicrobial activity in vitro and in vivo
54. Liposomal entrapment of neutrophil-derived peptide indolocodin endows it with in vivo anti-fungal activity
55. Living in the 'post-antibiotic era': Could the use of probiotics be an effective strategy?
56. Probiotics in man and animals
57. Probiotics and prebiotics: Microflora management for improved gut health
58. Bacteria and yeasts in the treatment of acute and chronic infectious diarrhea. Part I. Bacteria
59. Bacteria and yeasts in the treatment of acute and chronic infectious diarrhea. Part II. Yeasts
60. Sacchamromyces boulardii for Clostridium difficile-associated enteropathies in infants
61. Bacteriocins; nature, function and structure